Bold Leadership with More than 100 Years of Combined Experience.
William C. Buhles
Bill is a pharmaceutical scientist who has served as a clinical leader bringing life-saving medicines to market including the antiviral drug ganciclovir. Beginning in 1983, Dr. Buhles designed and ran Phase I, II, and III clinical trials in virology, oncology, and transplantation and oversaw later stages of drug development including authoring and submitting new drug applications to the FDA and European Union. He worked at Roche, Syntex Corporation, Gilead, and Otsuka America Pharmaceuticals. Dr. Buhles holds a Ph.D. in Microbiology and Immunology and a Doctor of Veterinary Medicine, both from the University of California, Davis.
Jacob P. Lalezari
Jay is the Chief Executive Officer and Director of Quest Clinical Research in San Francisco and has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer. He has published many research papers and presented research at numerous international conferences. Dr. Lalezari holds an M.A. degree in English Literature from the University of Virginia and earned his M.D. at the University of Pennsylvania.
David is the Chief Executive Officer of Rice’s Pharmacy, one of the largest retail pharmacies in Kentucky. He oversees payer engagement, purchasing/procurement, workflow efficiency, and patient experience. He is an engineer by training with expertise in data analytics, process optimization, and automation. He earned his Master’s Degree in Engineering and at the University of Louisville, Kentucky.
Donna is Founder and Strategic Advisor to Regulatory Professionals Inc. (RPI), a Division of Premier Research, where she currently serves as an advisor and holds an observer seat on the Board of Directors. Donna brings more than 35 years of experience developing drugs in the biotech and pharmaceutical industries. She has led teams of professionals with deep preclinical, clinical, and CMC expertise in the development of small molecules, biologics, cell-based therapies, and combination products through all phases of development, including preparation of marketing applications and post-approval activities. Donna started her career at Syntex in discovery research and later joined its worldwide regulatory affairs department (acquired by Roche) and led regulatory affairs departments at several biotech start-ups. She holds a BS degree in Biochemistry from the University of California, Davis, and an MBA from Santa Clara University.
Terri is a Board member and the Executive Director at NP2, and brings more than 30-years of leadership experience in the nonprofit sector with particular expertise in fundraising, marketing, strategic planning, and organizational development. Throughout her three decades of working with nonprofit organizations large and small, Terri has remained committed to helping organizations see the big picture while supporting them in taking the necessary action steps to achieve their goals. Terri earned a Bachelor’s Degree in Sociology and a Master’s Degree in Public Administration with an emphasis in nonprofit management from San Francisco State University. She later returned to her alma mater to teach a post-graduate course in Strategic Planning.
Jon is senior counsel in the drug and device regulatory and healthcare law practice of Wilson Sonsini Goodrich & Rosati. He brings many years of experience to the firm, regularly advising clients in the medical device, diagnostic, pharmaceutical, and biotechnology fields on a variety of regulatory and healthcare issues, such as FDA compliance, clinical studies, FDA product approvals and clearances, labeling, advertising, and promotional matters. Jon’s prior experience includes a long tenure as senior counsel at Syntex Corporation before its acquisition by Roche. Jon earned his Bachelor’s Degree in French from Yale University, his Master’s Degree in Education from Butler University, and his Juris Doctorate from Santa Clara University.
Leslie is the Chief Operating Officer at BAL, one of the world’s largest global immigration and mobility services providers. Prior to BAL, Leslie held several senior legal and operational roles at an AmLaw and Global 100 law firm, The Medicines Company (now part of Novartis), and practiced law privately. She has taught as an Adjunct Professor of Law and earlier in her career worked for the United States Congress. She received her Bachelor of Arts degree from Boston College and her Juris Doctor from Seton Hall University School of Law. Leslie has also completed post-graduate pharmaceutical executive education at The Wharton School at the University of Pennsylvania.